SCHEMBL9588277

SCHEMBL9588277

CCC(C(=O)OCCN(CC)CCN(CC)CCOC(=O)C(CC)c1ccccc1)c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.78
LMNA P02545 2/20 0.67
CYP1A2 P05177 2/20 0.67
CYP2D6 P10635 2/20 0.67
CYP3A4 P08684 3/20 0.65
ALDH1A1 P00352 2/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
CHRM1 P11229 7/20 0.55
CHRM2 P08172 6/20 0.54
CHRM3 P20309 5/20 0.54
CHRM4 P08173 3/20 0.54
HTR1A P08908 1/20 0.54
ADRA2A P08913 1/20 0.54
DRD1 P21728 1/20 0.54
SLC6A2 P23975 1/20 0.54
ADRA1A P35348 1/20 0.54
OPRM1 P35372 1/20 0.54
DRD3 P35462 1/20 0.54
SLC6A3 Q01959 1/20 0.54
KCNH2 Q12809 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9588408 0.96 KDM4E (0.76) KDM4ELMNACYP1A2CYP2D6CYP3A4
Butetamate SCHEMBL1643343 0.95 KDM4E (0.84) KDM4ELMNACYP1A2CYP2D6CYP3A4
Oxalic Acid SCHEMBL9589927 0.93 KDM4E (0.72) KDM4ELMNACYP1A2CYP2D6CYP3A4
Butetamate SCHEMBL8721011 0.92 KDM4E (0.78) KDM4ELMNACYP1A2CYP2D6CYP3A4
Butamirate SCHEMBL668881 0.87 KDM4E (1.00) KDM4ELMNACYP1A2CYP2D6CYP3A4
Butetamate SCHEMBL7339744 0.86 KDM4E (0.70) KDM4ELMNACYP1A2CYP2D6CYP3A4
Butetamate SCHEMBL317018 0.84 KDM4E (1.00) KDM4ELMNACYP1A2CYP2D6CYP3A4
SCHEMBL9588998 0.84 KDM4E (0.63) KDM4ELMNACYP1A2CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL26100 0.83 CYP3A4 (0.70) KDM4ELMNACYP1A2CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL9588751 0.82 KDM4E (0.61) KDM4ELMNACYP1A2CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5190946-A Piperazine compounds restore sensitivity to drug resistant cancer cells HOFFMANN-LA ROCHE INC. (US) 1993-03-02 US disclosed
EP-0443569-A2 Diamine derivatives and their use in oncology F. HOFFMANN-LA ROCHE AG (CH) 1991-08-28 EP disclosed